Materials and methods
tumor
TUMOR
The study was a phase 1 clinical trial offered at Mayo Clinic in Rochester, MN. The primary objective was to determine the safety profile of VSV-IFNβ-TYRP1 administered via IV and IT routes. Secondary objectives were to gather preliminary data on tumor response and progression-free survival (PFS). We investigated both viral and immunological correlates.